Use of gemtuzumab ozogamicin in relapsed refractory acute myeloid leukemia: Multi-center real life data from Turkey

We retrospectively evaluated the use of gemtuzumab ozogamicin (GO) in relapsed refractory (R/R) acute myeloid leukemia (AML) patients. Twenty-one CD33 positive R/R AML patients who received GO as a single agent in 4 hematology centers were included in this study. The median age was 59, and the media...

Descripción completa

Guardado en:
Detalles Bibliográficos
Autores principales: Ayşe Hilal Eroğlu Küçükdiler, İrfan Yavaşoğlu, Cem Selim, Cansu Atmaca Mutlu, Abdullah Karakuş, Mahmut Bakır Koyuncu, Oktay Bilgir, Orhan Ayyıldız, Eyüp Naci Tiftik, Ali Zahit Bolaman
Formato: article
Lenguaje:EN
Publicado: Elsevier 2021
Materias:
Acceso en línea:https://doaj.org/article/45ce0eecfb3e4771bd9551a8db580cf6
Etiquetas: Agregar Etiqueta
Sin Etiquetas, Sea el primero en etiquetar este registro!